<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36348166</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0100</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Endocrine</Title><ISOAbbreviation>Endocrine</ISOAbbreviation></Journal><ArticleTitle>Novel IGFALS mutations with predicted pathogenetic effects by the analysis of AlphaFold structure.</ArticleTitle><Pagination><StartPage>292</StartPage><EndPage>295</EndPage><MedlinePgn>292-295</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12020-022-03244-z</ELocationID><Abstract><AbstractText Label="PURPOSE">According to the American College of Medical Genetics (ACMG) classification, variants of uncertain significance (VUS) are gene variations whose impact on the disease risk is not yet known. VUS, therefore, represent an unmet need for genetic counselling. Aim of the study is the use the AlphaFold artificial intelligence algorithm to predict the impact of novel mutations of the IGFALS gene, detected in a subject with short stature and initially classified as VUS according to the ACMG classification.</AbstractText><AbstractText Label="METHODS">A short-stature girl and her parents have been investigated. IGFALS mutations have been detected through clinical exome and confirmed by Sanger sequencing. The potential presence of co-occurring gene alterations was investigated in the proband by whole exome and CGH array. Structure of the ALS protein (encoded by the IGFALS gene) was evaluated through the AlphaFold artificial intelligence algorithm.</AbstractText><AbstractText Label="RESULTS">Two IGFALS variants were found in the proband: c.1349T&#x2009;&gt;&#x2009;C (p.Leu450Pro) and c.1363_1365delCTC (p.Leu455del), both classified as VUS, according to ACMG. Parents' analysis highlighted the in trans position of the two variants. AlphaFold showed that the mutated positions were found the concave side a horseshoe structure of the ALS protein, likely interfering with protein-protein interactions. According to a loss of function (LoF) effect of the two variants, reduced levels of the IGF1 and IGFBP-3 proteins, as well as a growth hormone (GH) excess were detected in the proband's serum.</AbstractText><AbstractText Label="CONCLUSIONS">By using the AlphaFold structure we were able to predict two IGFALS gene mutations initially classified as VUS, as potentially pathogenetic. Our proof-of-concept showed a potential application of AlphaFold as tool to a better inform VUS interpretation of genetic tests.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franzoni</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>SOC Istituto di Genetica Medica, Azienda Sanitaria Universitaria Friuli Centrale Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldan</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>SOC Istituto di Genetica Medica, Azienda Sanitaria Universitaria Friuli Centrale Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passon</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>SOC Istituto di Genetica Medica, Azienda Sanitaria Universitaria Friuli Centrale Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mio</LastName><ForeName>Catia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dipartimento di Area Medica, Universit&#xe0; di Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driul</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>SOC Clinica Pediatrica, Azienda Ospedaliero-Universitaria, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cogo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Area Medica, Universit&#xe0; di Udine, Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SOC Clinica Pediatrica, Azienda Ospedaliero-Universitaria, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogolari</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze matematiche, Informatiche e Fisiche, Universit&#xe0; di Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Aurizio</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>SOC Istituto di Patologia Clinica Azienda Sanitaria Universitaria Friuli Centrale Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damante</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>SOC Istituto di Genetica Medica, Azienda Sanitaria Universitaria Friuli Centrale Udine, Udine, Italy. giuseppe.damante@uniud.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Area Medica, Universit&#xe0; di Udine, Udine, Italy. giuseppe.damante@uniud.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Endocrine</MedlineTA><NlmUniqueID>9434444</NlmUniqueID><ISSNLinking>1355-008X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Exome</Keyword><Keyword MajorTopicYN="N">IGFALS</Keyword><Keyword MajorTopicYN="N">Mutation</Keyword><Keyword MajorTopicYN="N">Short stature</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36348166</ArticleId><ArticleId IdType="doi">10.1007/s12020-022-03244-z</ArticleId><ArticleId IdType="pii">10.1007/s12020-022-03244-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>R.C. Baxter, Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J. Clin. Endocrinol. Metab. 70, 1347&#x2013;1353 (1990)</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem-70-5-1347</ArticleId></ArticleIdList></Reference><Reference><Citation>J.B. Janosi, P.A. Ramsland, M.R. Mott, S.M. Firth, R.C. Baxter, P.J. Delhanty, The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes. Structural determination by molecular modeling and electron microscopy. J. Biol. Chem. 274, 23328&#x2013;23332 (1999)</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.33.23328</ArticleId></ArticleIdList></Reference><Reference><Citation>A. David, L.A. Kelley, M.J. Sternberg, A new structural model of the acid-labile subunit: pathogenetic mechanisms of short stature-causing mutations. J. Mol. Endocrinol. 49, 213&#x2013;220 (2012)</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-12-0086</ArticleId></ArticleIdList></Reference><Reference><Citation>R.C. Baxter, Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab. 278, E967&#x2013;E976 (2000)</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.2000.278.6.E967</ArticleId></ArticleIdList></Reference><Reference><Citation>H.M. Domen&#xe9;, S.V. Bengolea, A.S. Mart&#xed;nez, M.G. Ropelato, P. Pennisi, P. Scaglia, J.J. Heinrich, H.G. Jasper, Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N. Engl. J. Med. 350, 570&#x2013;577 (2004)</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa013100</ArticleId></ArticleIdList></Reference><Reference><Citation>V. Hwa, M. Fujimoto, G. Zhu, W. Gao, C. Foley, M. Kumbaji, R.G. Rosenfeld, Genetic causes of growth hormone insensitivity beyond GHR. Rev. Endocr. Metab. Disord. 22, 43&#x2013;58 (2021)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-020-09603-3</ArticleId></ArticleIdList></Reference><Reference><Citation>W. H&#xf6;gler, D.D. Martin, N. Crabtree, P. Nightingale, J. Tomlinson, L. Metherell, R. Rosenfeld, V. Hwa, S. Rose, J. Walker, N. Shaw, T. Barrett, J. Frystyk, IGFALS gene dosage effects on serum IGF-I and glucose metabolism, body composition, bone growth in length and width, and the pharmacokinetics of recombinant human IGF-I administration. J. Clin. Endocrinol. Metab. 99, E703&#x2013;E712 (2014)</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2013-3718</ArticleId></ArticleIdList></Reference><Reference><Citation>O.V. Fofanova-Gambetti, V. Hwa, J.M. Wit, H.M. Domene, J. Argente, P. Bang, W. H&#xf6;gler, S. Kirsch, C. Pihoker, H.K. Chiu, L. Cohen, C. Jacobsen, H.G. Jasper, G. Haeusler, A. Campos-Barros, E. Gallego-G&#xf3;mez, R. Gracia-Bouthelier, H.A. van Duyvenvoorde, J. Pozo, R.G. Rosenfeld, Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortium. J. Clin. Endocrinol. Metab. 95, 4184&#x2013;4191 (2010)</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2010-0489</ArticleId></ArticleIdList></Reference><Reference><Citation>E. I&#x15f;&#x131;k, B. Haliloglu, J. van Doorn, H. Demirbilek, S.A. Scheltinga, M. Losekoot, J.M. Wit, Clinical and biochemical characteristics and bone mineral density of homozygous, compound heterozygous and heterozygous carriers of three novel IGFALS mutations. Eur. J. Endocrinol. 176(6), 657&#x2013;667 (2017)</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-16-0999</ArticleId></ArticleIdList></Reference><Reference><Citation>S. Domen&#xe9;, H.M. Domen&#xe9;, The role of acid-labile subunit (ALS) in the modulation of GH-IGF-I action. Mol. Cell Endocrinol. 518, 111006 (2020)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2020.111006</ArticleId></ArticleIdList></Reference><Reference><Citation>I. Ueki, G.T. Ooi, M.L. Tremblay, K.R. Hurst, L.A. Bach, Y.R. Boisclair, Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc. Natl. Acad. Sci. USA 97, 6868&#x2013;6873 (2000)</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.120172697</ArticleId></ArticleIdList></Reference><Reference><Citation>J.W. Prokop, T. May, K. Strong, S.M. Bilinovich, C. Bupp, S. Rajasekaran, E.A. Worthey, J. Lazar, Genome sequencing in the clinic: the past, present, and future of genomic medicine. Physiol. Genom. 50, 563&#x2013;579 (2018)</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00046.2018</ArticleId></ArticleIdList></Reference><Reference><Citation>J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. &#x17d;&#xed;dek, A. Potapenko, A. Bridgland, C. Meyer, S.A.A. Kohl, A.J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A.W. Senior, K. Kavukcuoglu, P. Kohli, D. Hassabis, Highly accurate protein structure prediction with AlphaFold. Nature 596, 583&#x2013;589 (2021)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId></ArticleIdList></Reference><Reference><Citation>H.A. van Duyvenvoorde, M.J. Kempers, T.B. Twickler, J. van Doorn, W.J. Gerver, C. Noordam, M. Losekoot, M. Karperien, J.M. Wit, A.R. Hermus, Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur. J. Endocrinol. 159, 113&#x2013;120 (2008)</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-08-0081</ArticleId></ArticleIdList></Reference><Reference><Citation>H.L. Storr, R. Prasad, I.K. Temple, L.A. Metherell, M.O. Savage, J.M. Walker, Heterogeneity of the growth phenotype and birth size in acid-labile subunit (ALS) deficiency. J. Endocrinol. Investig. 38, 407&#x2013;412 (2015)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-014-0195-1</ArticleId></ArticleIdList></Reference><Reference><Citation>S.M. Firth, X. Yan, R.C. Baxter, D440N mutation in the acid-labile subunit of insulin-like growth factor complexes inhibits secretion and complex formation. Mol. Endocrinol. 25, 307&#x2013;314 (2011)</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2010-0295</ArticleId></ArticleIdList></Reference><Reference><Citation>L.C. Martucci, M.L. Guti&#xe9;rrez, L.M. Karabatas, P.A. Scaglia, R.A. Rey, H.M. Domen&#xe9;, H.G. Jasper, S. Domen&#xe9;, Assessment of pathogenicity of natural IGFALS gene variants by in silico bioinformatics tools and in vitro functional studies. Mol. Cell Endocrinol. 429, 19&#x2013;28 (2016)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2016.03.031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>